Hims & Hers Stock Fell 32% As Profit Slipped
Shares of Hims & Hers Health (HIMS) fell 32.2% between August 18 and November 16, 2026, while the S&P 500 lost 3.3%.
Archived explainer. For the current picture see today's HIMS page.
HIMS & HERS HEALTH I A (HIMS) is down -7.30% in the latest session. Our newswire has captured 3 stories on HIMS across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).
Hims & Hers Health (HIMS) shares fell 7.30% to $17.20, driven by a recent 32.2% decline in stock price that outpaced the broader market. The primary driver for the latest session was the company’s Q3 2026 financial results, which showed strong revenue growth but a less impressive bottom line.
The stock has experienced a significant drawdown, losing 32.2% between August 18 and November 16, 2026, while the S&P 500 lost only 3.3% over the same period. Recent filings indicate the company reported Q3 2026 financial results and updated its 2026 outlook. While revenue grew 29.8% on a trailing twelve-month basis, the company remains unprofitable with a trailing twelve-month EPS of negative $0.83 and a net margin of negative 6.7%.
External developments have added to the pressure. Hims & Hers faces an expanded FTC lawsuit and a securities class action lawsuit with a lead plaintiff deadline. Additionally, the company announced an agreement with Eli Lilly to expand access to obesity medications. Despite these headwinds, one analyst rated the stock a Strong Buy with a price target of $23.8, citing international expansion as a key growth driver.
The intraday session opened at $18.68, a 0.6% gap up from the prior close of $18.56. The stock hit a session high of $18.73 at 7:00 AM ET before sliding to a low of $17.17 at 11:35 AM ET. Volume stood at 5.3 million shares, which is 0.4 times the three-month daily average. The stock has printed 30 fresh 52-week lows on November 17, 2026, and sits near the bottom of its 52-week range of $13.74 to $40.99.
Over the last 8 sessions, the stock has moved down 22.9%. Insider activity shows 13 sells totaling $3.8 million in the last 90 days, with no buys recorded. Recent sales include shares sold by General Counsel Boughton Soleil and CFO Okupe Oluyemi. Unusual options activity in the last 36 hours featured a large put premium of $853,000 compared to a call premium of $180,000.
Investors should monitor the impact of the expanded FTC lawsuit and the securities class action proceedings. The upcoming reaction to the company’s international expansion strategy and the continued trend of insider selling will also be key factors to observe.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Shares of Hims & Hers Health (HIMS) fell 32.2% between August 18 and November 16, 2026, while the S&P 500 lost 3.3%.
Analyst rates Hims & Hers Health a Strong Buy: $23.8 implies roughly 20% upside toward a 15% annual return, led by international expansion.
The company generated strong growth last quarter, but its bottom line didn't look nearly as impressive.
More on HIMS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier HIMS move explainers: 2026-11-17 · 2026-11-11 · 2026-11-10 · 2026-11-09 · 2026-10-09 · 2026-09-30 · 2026-09-08 · 2026-08-28 · 2026-08-27 · 2026-08-26 · 2026-08-25 · 2026-08-24 · 2026-08-20 · 2026-08-19